Biomarkers for Alzheimer's disease (AD) should meet several criteria, including simplicity of testing. Inappropriate activation of the complement cascade has been implicated in the pathogenesis of AD. Complement factor H (CFH) is a regulator of the cascade, but studies on plasma CFH levels in AD have provided mixed results. This study compared plasma CFH levels in 317 AD cases with 254 controls using an immunodiffusion assay. The sample had an 80% power to detect a difference of 23 mg/L between cases and controls, but no difference was evident. Plasma CFH may not be a suitable biomarker for AD.
Williams, M. A., Haughton, D., Stevenson, M., Craig, D., Passmore, A. P., & Silvestri, G. (2015). Plasma Complement factor H in Alzheimer's Disease. Journal of Alzheimer's disease : JAD, 45(2), 369-372. https://doi.org/10.3233/JAD-142742